TABLE 2.

All-course five-fold cross-validation results by chemotherapy regimen, in Step 2 regimen and start-date identification.

Random Forest
	Fold 1		Fold 2		Fold 3		Fold 4		Fold 5
	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity
ADE 10	0.92	0.84	0.92	0.85	0.88	0.88	0.88	0.89	0.90	0.82
ADE 10 GMTZ	0.91	0.74	0.89	0.83	0.95	0.64	0.89	0.85	0.93	0.84
ADE 8	0.85	0.81	0.88	0.89	0.84	0.88	0.87	0.87	0.82	0.88
AE	0.91	0.85	0.91	0.90	0.93	0.88	0.90	0.94	0.94	0.88
HDAraC-C	0.90	0.88	0.90	0.90	0.85	0.90	0.89	0.87	0.86	0.86
MA	0.86	0.92	0.87	0.92	0.85	0.95	0.87	0.94	0.85	0.91
Logistic Regression
	Fold 1		Fold 2		Fold 3		Fold 4		Fold 5
	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity
ADE 10	0.84	0.75	0.84	0.72	0.78	0.76	0.74	0.77	0.81	0.72
ADE 10 GMTZ	0.96	0.67	0.93	0.70	0.94	0.69	0.90	0.78	0.95	0.71
ADE 8	0.79	0.69	0.81	0.76	0.77	0.69	0.76	0.70	0.75	0.79
AE	0.85	0.80	0.87	0.88	0.88	0.86	0.84	0.90	0.85	0.88
HDAraC-C	0.86	0.35	0.84	0.35	0.65	0.39	0.76	0.32	0.81	0.33
MA	0.81	0.76	0.80	0.77	0.76	0.83	0.84	0.78	0.84	0.75
Support Vector Machine
	Fold 1		Fold 2		Fold 3		Fold 4		Fold 5
	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity
ADE 10	0.92	0.83	0.91	0.81	0.95	0.85	0.91	0.87	0.91	0.82
ADE 10 GMTZ	0.91	0.83	0.94	0.90	0.93	0.88	0.86	0.93	0.92	0.94
ADE 8	0.86	0.79	0.89	0.84	0.86	0.87	0.85	0.88	0.83	0.89
AE	0.88	0.81	0.91	0.88	0.92	0.87	0.89	0.91	0.91	0.88
HDAraC-C	0.89	0.59	0.88	0.65	0.79	0.64	0.84	0.62	0.85	0.60
MA	0.86	0.91	0.85	0.90	0.83	0.92	0.86	0.94	0.83	0.90

Abbreviations: ADE, ara-C (cytarabinel+daunorubicin+etoposide; AE, ara-C+etoposide; GMTZ, gemtuzumab; HDAraC-C, high-dose ara-C+asparaginase; MA, mitoxantrone+ara-C.